Evaluating New Breast Cancer Treatments
Phase 1/2
792
about 13 years
18+
16 sites in CA, CO, FL +5
What this study is about
Researchers are testing multiple treatment combinations in people with advanced or locally advanced breast cancer. The trial will be done in two stages, starting with a group of participants who have never received immunotherapy and then including those who have progressed on previous treatments. Participants may receive different treatment combinations during the second stage if they experience disease progression.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Abemaciclib
- 2.Take Atezolizumab
- 3.Take Atirmociclib
- +3 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
abemaciclib, atezolizumab, cdk inhibitor, bevacizumab, capecitabine, carboplatin, empagliflozin (SGLT2 inhibitor; increases glucose excretion in urine), eribulin
oral (Oral Tablet), injection (Injection), infusion, injection, oral, oral (Oral Capsule)
Primary: Objective Response Rate (ORR)
Secondary: Disease Control Rate (DCR), Duration of Response (DOR), Overall Survival (OS), Overall Survival (at specific time-points), Percentage of Participants with Adverse Events, Progression Free Survival (PFS)
Oncology